Experimental and clinical studies impressively demonstrate that angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) significantly reduce proteinuria and retard progression of glomerular disease. The underlying intraglomerular mechanisms are not yet fully elucidated. As podocyte injury constitutes a critical step in the pathogenesis of glomerular proteinuria, beneficial effects of ACEI and ARB may partially result from interference with a local renin angiotensin system (RAS) in podocytes. The knowledge of expression and function of a local RAS in podocytes is limited.
Introduction:
The renin angiotensin system (RAS) plays a crucial role in controlling blood pressure, fluid balance and electrolyte homeostasis (48, 51) . Enzymatic cleavage by renin and angiotensin converting enzyme (ACE) leads to the conversion of angiotensinogen via angiotensin I to its main effector molecule angiotensin II (Ang II). Apart from its hemodynamic action, Ang II is capable of inducing a multitude of non-hemodynamic effects such as induction of oxygen radicals, cytokines, stimulation of collagen synthesis, apoptosis, proliferation and hypertrophy (20, 51) . Within the glomerulus, Ang II reduces the ultrafiltration coefficient and modulates glomerular capillary permselectivity leading to proteinuria, initiating and increasing subsequent tubulointerstitial injury (3, 26, 42) . Acting as growth hormone, Ang II contributes to the pathogenesis of glomerulosclerosis (20) .
Clinical studies have impressively demonstrated that ACE inhibitors (ACEI) markedly reduce proteinuria and progression of glomerular disease (28, 31, 43) . Furthermore, angiotensin type 1 receptor blockers (ARB) have clearly been shown to retard the progression of diabetic nephropathy (6, 29) . Most recently, the addition of ARB to ACEI treatment further reduced proteinuria (2, 27 ).
The podocyte is the most differentiated cell type within the glomerulus. Synthesizing various components of the glomerular basement membrane and the slit diaphragm, it is crucially involved in the maintenance of the glomerular filtration barrier (40) . Podocyte injury leads to alterations of the foot process/slit diaphragm complex with loss of glomerular permselectivity resulting in proteinuria (40) .
Interestingly, little is known about expression and function of the RAS in podocytes. In this regard, one may hypothesize that the antiproteinuric effects of ACEI or ARB may partially result from interference with a local RAS in podocytes. This prompted us to Liebau et al. 4 Final accepted version F- 00475-2004.R1 specifically investigate expression and function of components of the renin angiotensin system in differentiated human podocytes.
Methods:

Cell culture
The conditionally immortalized human podocyte cell line has been developed as recently described by transfection with the temperature-sensitive SV40 T-gene (44) .
Proliferating at a temperature of 33°C, these cells transform into a quiescent, differentiated phenotype after transfer to 37°C. Cells then stain positive for the in vivo podocyte markers synaptopodin, nephrin, podocin, CD2AP, ZO-1, α-, β-, γ-catenins, and P-cadherin (44) . For experiments, cells between passage 10 and 18 were seeded at 37 °C into 6-well plates, 24-well plates or flasks and cultured in standard RPMI media containing 10 % fetal calf serum (Biochrom, Berlin, Germany), 2.5 mM L-glutamin, 0.1 mM sodium pyruvate, 1 g/L non-essential amino acids (all Seromed, Berlin, Germany) and insulin-transferrin-sodium selenite supplement (Boehringer, Mannheim, Germany), 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco, Eggenstein, Germany) for at least 7 days until cells were differentiated showing an arborized morphology.
RT-PCR for components of the renin-angiotensin system
The RNA preparation, the reverse transcription and the polymerase chain reaction amplification (PCR) were performed according to the method recently described (14) . In brief, the total RNA from cultured human podocytes was isolated with guanidinium/acid phenol/chloroform extraction and the amount of RNA was measured with spectrophotometry. For first strand synthesis, total RNA from podocytes was mixed in 5x reverse transcription buffer and completed with 0.5 mM dNTP, 10 µM random hexanucleotide primer, 10 mM dithiothreitol, 0.02 U RNAse inhibitor/ng RNA and 100 U Liebau et al. Table 1 ). The amplification products of 10 µl of each PCR reaction were separated on a 1.5% agarose gel, stained with ethidium bromide, and visualized by UV irradiation. The primer oligonucleotides were selected from published cDNA sequences and are depicted in Table 1 . All primers are noted in 5'-3' direction.
Immunohistochemistry of kidney cortex
Normal kidney cortex was obtained from nephrectomy specimens. Fixation and preparation of tissue for immunohistochemical analyses were performed using standard techniques. In brief, kidneys were perfused after removal with cold (4°C) phosphatebuffered saline (PBS) followed by 4 % formaldehyde. Kidneys then were incubated for 24 h at 4°C in 4 % formaldehyde solution, embedded in paraffin and cut into 4 µm thick slices. Slices were deparaffinized in xylol for 1 h, gradually hydrated through graded alcohols (100 to 70 %) and washed in deionized water. After incubation in 1 % H 2 O 2 for 30 minutes, slices were rehydrated with PBS, and antigen unmasking was performed by boiling slices in 10 mM citrate buffer (pH 6) for AT 1 and WT1 or EDTA (pH 9) for AT 2 for 
Immunocytochemistry of cultured human podocytes
The immunolabeling was done as previously described (34). Briefly, coverslips were fixed with 2% paraformaldehyde and 4% sucrose in PBS for 10 min, and were then permeabilized with 0.3% Triton X-100 (Sigma-Aldrich, Munich, Germany) in PBS for 10 min. Nonspecific binding sites were blocked with 2% FCS, 2% bovine serum albumin, and fish gelatine (Sigma-Aldrich) in PBS for 30 min. Primary (rabbit anti-AT 1 and rabbit anti-AT 2 , both Santa Cruz) and secondary antibodies were applied in a 1:100 dilution according to standard techniques, and the coverslips were mounted on glass slides with 15% Mowiol (Calbiochem, La Jolla, CA) and 50% glycerol in PBS. After being washed with PBS, bound primary Abs were detected using FITC-conjugated cat anti-rabbit IgG (Santa Cruz). As controls, primary Abs either were omitted or boiled at 99° C for 10 min and used thereafter. Micrographs were taken on a microscope equipped for epiluminescence (Zeiss Axiophot).
Western blotting
Western blotting was performed using standard techniques. In brief, cells were washed once with PBS, scraped with lysis buffer containing 2 mM EDTA, 2 mM EGTA, 100 mM NaCl, 20 mM Tris, 0.1% SDS, 1% NP-40, 2 mM PMSF and proteinase inhibitor cocktail 
Measurements of intracellular cAMP
Podocytes were cultured in 6-well plates. They were kept at 37°C and rinsed with a physiological Ringer´s type solution. After pre-incubation with 0.5 M 3-isobutyl-Imethylxanthine (IBMX; RBI, Köln, Germany) for 5 min, cells were exposed to the added agents. To terminate the assay, the supernatants were rapidly removed and cells were 
Measurements of angiotensin II secretion
Podocytes were cultured in 6-well plates. They were kept at 37°C and medium was 
Mechanical stress experiments
Differentiated human podocytes were seeded in six-well plates with a flexible bottom (Bioflex; Flexcell International, Hillsborough, NC). The flexible silicone membranes were coated with collagen IV to facilitate cell attachment. After 3 d, the six-well plate was mounted on a Plexiglas manifold connected to a custom-built apparatus, which induced cyclic variations in air pressure below and above atmospheric pressure. Cyclic pressure variations caused upward and downward motion of the silicone membranes. Pressure amplitude was chosen to give a maximum up-and downward deflection of the membrane center of 6 mm, being equal to an increase in membrane area by 11%, or 5% mean linear cell strain. Cycle frequency was adjusted to 0.5 Hz.
Measurements of LDH release from podocytes
To assess cytotoxicity, LDH release was measured with a routine autoanalyzer 
TUNEL procedure
DNA strand breaks were identified by TUNEL (TdT-mediated dUTP nick end labeling) reaction using an in situ cell death detection kit (Roche) according to manufacturers instructions. In brief: First, podocytes were cultured on coverslips incubated for indicated times, then washed with PBS fixed in 4% paraformaldehyde at room temperature for 30 minutes. Subsequently, the cytoplasma membrane was permeabilized with 0.1% Triton X-100 for 2 min on ice. After two times washing cells were incubated with TUNEL reaction mixture for 60 minutes at 37°C . Samples were directly analysed under a fluorescence microscope by detection at 550 nm. Cells labeled in absence of TdT were always used as negative controls, whereas cells pretreated with DNase after permeabilization were used as positive control.
Chemicals
Unless otherwise indicated, chemicals were purchased from Sigma. Figure 1 ). PCR primers and conditions are depicted in Table 1 .
AT receptor expression in differentiated human podocytes
Western blot analyses consistently revealed protein expression both of the AT 1 and AT 2 receptor in human podocytes (AT 1 receptor: Figure 2A , lane 1+2; AT 2 receptor: Figure   2B , lane 1+2), the specificity of which was confirmed using respective blocking peptides (AT 1 receptor: Figure Figure 5C ).
Angiotensin II does not increase the cyclic AMP concentration in differentiated human podocytes
Recently it has been reported that angiotensin II elevates the cyclic AMP concentration in rat glomerular epithelial cells in culture (46, 47) . To address this issue in differentiated human podocytes, cAMP concentration was measured in separate experiments. Within a time course of 2 h, angiotensin II (1 µM) did not increase cAMP production in human podocytes ( Figure 6A ). To exclude rapid cAMP degradation by phosphodiesterases during the experiments, the specific phosphodiesterase inhibitor 3-isobutyl-Imethylxanthine (IBMX, 500 µM) was added. Again, no elevation of cAMP levels was observed ( Figure 6B ). In the presence of IBMX, the membrane-permeable adenylate Final accepted version F-00475-2004.R1
cyclase activator forskolin concentration-dependently increased cAMP production. In this setting, angiotensin II had no additive effect ( Figure 6C ).
Differentiated human podocytes secrete angiotensin II
After having detected mRNA expression of key components of a local RAS, we were interested in secretion of angiotensin II as the final RAS effector by differentiated human podocytes. As detected by ELISA, human podocytes secrete angiotensin II ( Figure 7A ).
However, neither the specific renin inhibitor remikiren (10 µM) nor the ACE inhibitor captopril (10 µM) nor the chymase inhibitor chymostatin (100 µM) nor a combination of the three inhibitors did significantly reduce angiotensin II secretion of podocytes ( Figure   7A ). Further, angiotensin II secretion of podocytes was not altered by mechanical stress ( Figure 7B ).
Angiotensin II does not increase LDH release in differentiated human podocytes
To test for podocyte damage induced by angiotensin II, LDH release experiments were performed. Even upon prolonged stimulation at high angiotensin II concentration (24h and 48h, 1 µM), LDH release was not significantly increased (n=6-12; Figure 8 ).
Angiotensin II increases staurosporine-induced apoptosis in differentiated human podocytes
As measured by flow cytometry, staurosporine (1 µM, 24h) induced apoptosis of differentiated human podocytes. Stimulation of podocytes with angiotensin II (1 µM) in addition to staurosporine increased the rate of apoptosis induced by staurosporine only
(1 µM). However, stimulation with angiotensin II only did not alter the rate of apoptosis ( Figure 9 ). These findings were confirmed by TUNEL assay (data not shown). Indirect evidence suggests that Ang II is capable of disturbing podocyte biology:
Spontaneous proteinuria in Munich Wistar Froemter (MWF) rats has been attributed to an altered distribution of the slit diaphragm protein zonula occludens-1, both of which were prevented by the ACEI lisinopril (30). In experimental diabetic nephropathy, podocyte foot process broadening was attenuated both by the ACEI ramipril and the ARB valsartan (32). In animal models of diabetic nephropathy, reduction of nephrin expression was attenuated by the ACEI perindopril (19) and by the ARB valsartan and irbesartan (5, 8) . Selective overexpression of the AT 1 receptor in podocytes in rats most recently has been reported to lead to protein leakage and structural podocyte damage progressing to glomerulosclerosis (17) . In a recent renal biopsy study, placebo-treated patients with diabetic nephropathy showed a marked reduction of glomerular nephrin Final accepted version F-00475-2004.R1 expression compared to non-diabetic control subjects, whereas nephrin expression in patients treated with the ACEI perindopril was similar to the control group (25). Another renal biopsy study revealed reduction of glomerular nephrin expression both in type 1 and type 2 diabetic patients compared to controls (10) . These findings suggest direct rather than indirect Ang II effects on podocytes, which furthermore are independent of its hemodynamic actions.
We show for the first time that differentiated human podocytes express all RAS components required to generate Ang II. Further, secretion of Ang II by resting human podocytes was observed. Ang II production most recently has been reported to occur in primary mouse podocytes exposed to mechanical strain (11). We exposed podocytes to mechanical strain under conditions known to affect podocytes (12) angiotensin receptor in podocytes (11, 13, 16, 39, 46, 49) . In some studies, AT 2 receptor expression likewise was detected in podocytes (11, 46, 49 Recently, Ang II has been reported to induce a concentration-dependent increase of cAMP in rat podocytes, which could only be blocked by simultaneous use of both AT 1 and AT 2 receptor blockers (46) . In patch-clamp experiments of podocytes in intact rat glomeruli, we recently were not able to demonstrate cellular responses to forskolin or 8-(4-chlorophenylthio)-cAMP (13). In the current study, differentiated human podocytes were stimulated either with Ang II alone or in the presence of the phosphodiesterase inhibitor IBMX to exclude rapid cAMP degradation. cAMP production was repetitively measured over a time course of 120 min. In these experiments, we did not observe induction of significant cAMP production by Ang II in differentiated human podocytes.
Using the adenylate cyclase activator forskolin in combination with IBMX, marked cAMP production was observed. However, this again was not augmented by addition of Ang II. Final accepted version F-00475-2004.R1
We conclude from these experiments that Ang II does not induce cAMP production in human podocytes.
Within the plethora of its biological effects, Ang II has been claimed to induce cell growth, proliferation and apoptosis (9, 48, 51) . Here it has been shown most recently that Ang II enhanced DNA synthesis in differentiated mouse podocytes, an effect which was markedly inhibited by the AT 1 receptor antagonist losartan, whereas the AT 2 receptor antagonist PD123319 was without effect (49) . In contrast, using a similar model of differentiated mouse podocytes another group reported exogenous Ang II to induce apoptosis (11) . Podocyte apoptosis induced by mechanical strain was significantly ameliorated by the AT 1 receptor antagonist losartan (11) . In the current study, LDH release and cell sorting experiments did not indicate podocyte damage even upon prolonged Ang II stimulation. However, Ang II did increase staurosporine-induced apoptosis. One may therefore speculate that once a pathological, e.g. inflammatory environment has induced podocyte damage, this may be markedly enhanced by local Ang II. In this context it is of specific note that intrarenal often exert systemic Ang II concentrations under pathophysiological conditions (45) . In these circumstances, a functional renin angiotensin system in human podocytes may transmit damage to this unique cell type.
Podocytes play a key role in the maintenance of the glomerular filtration barrier. Here we show for the first time that human podocytes possess a functionally active local RAS. They do not only respond to Ang II by activation of AT 1 receptors, but are further capable of directly producing Ang II. This RAS appears to be involved not only in physiological mechanisms, but also in pathological responses (11) . Inhibition of Ang II effects in podocytes might lower podocyte tonus, decrease the rate of apoptosis, and increase glomerular permselectivity (21). Based on these grounds, podocytes constitute an important target for ACE inhibitors and AT 1 receptor blockers (5, 8, 19, 25, 30, 32) . The combination of these two pharmacological drug classes has recently been shown to result in additive renoprotective effects both in non-diabetic and diabetic disease (33, 35).
Compelling evidence has accumulated that Ang II exerts a number of pathophysiological events in podocytes. Here, nephroprotection by ACE inhibitors and AT 1 receptor blockers in part can be spelled "podocyto-protection".
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